Aurinia Pharmaceuticals Inc. — Form 10-Q
Filed October 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Kevin Tang (CEO) and Michael Hearne (CFO) issued standard Sarbanes-Oxley 302 and 906 certifications for the Q3 2026 10-Q period ending September 30, 2026, filed October 29, 2026. Both officers attest to fair presentation of financial statements and effectiveness of disclosure controls and internal controls; no material weaknesses, significant deficiencies, or fraud disclosures are mentioned in these exhibits.
Why this rating
Routine SOX certification exhibits; boilerplate compliance document with no new factual disclosures, transactions, or control issues reported. Standard periodic filing requirement.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.